| Autor: |
Hamedani NS; Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, 53127 Bonn, Germany., Biswas A; Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, 53127 Bonn, Germany., Rudan O; Department of Integrated Oncology, CIO Bonn, University Hospital Bonn, 53127 Bonn, Germany., Tönges R; Department of Medicine 2, Hematology-Oncology Goethe University Hospital, 60590 Frankfurt am Main, Germany., Meyring C; Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, 53127 Bonn, Germany., Tolle F; Life and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany., Mayer G; Life and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany., Oldenburg J; Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, 53127 Bonn, Germany., Müller J; Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, 53127 Bonn, Germany., Pötzsch B; Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, 53127 Bonn, Germany. |
| Abstrakt: |
Coagulation factor XIII (FXIII) is a protransglutaminase which plays an important role in clot stabilization and composition by cross-linking the α- and γ-chains of fibrin and increasing the resistance of the clot to mechanical and proteolytic challenges. In this study, we selected six DNA aptamers specific for activated FXIII (FXIIIa) and investigated the functional characterization of FXIIIa after aptamer binding. One of these aptamers, named FA12, efficiently captures FXIIIa even in the presence of zymogenic FXIII subunits. Furthermore, this aptamer inhibits the incorporation of FXIII and α2-antiplasmin (α2AP) into fibrin(ogen) with IC 50 -values of 38 nM and 17 nM, respectively. In addition to FA12, also another aptamer, FA2, demonstrated significant effects in plasma-based thromboelastometry (rotational thromboelastometry analysis, ROTEM)-analysis where spiking of the aptamers into plasma decreased clot stiffness and elasticity ( p < 0.0001). The structure-function correlations determined by combining modeling/docking strategies with quantitative in vitro assays revealed spatial overlap of the FA12 binding site with the binding sites of two FXIII substrates, fibrinogen and α2AP, while FA2 binding sites only overlap those of fibrinogen. Taken together, these features especially render the aptamer FA12 as an interesting candidate molecule for the development of FXIIIa-targeting therapeutic strategies and diagnostic assays. |
